# Sex-Specific Plasma Metabolomic Signatures in COPD Reveal Creatine, Purine/Urate, and Bile-Acid Axes

**Authors:** Carme Casadevall, César Jessé Enríquez-Rodríguez, Alexandra Eliassaf, Ady Castro-Acosta, Rosa Faner, José Luis López-Campos, Eduard Monsó, Sergi Pascual-Guàrdia, Ramon Camps-Ubach, Borja G. Cosío, Alvar Agustí, Ori Shalev, Joaquim Gea

PMC · DOI: 10.3390/metabo16030178 · 2026-03-07

## TL;DR

The study finds sex-specific metabolic differences in COPD patients, highlighting creatine, purine/urate, and bile-acid pathways.

## Contribution

It identifies novel sex-specific plasma metabolomic signatures in COPD, revealing distinct metabolic axes influenced by sex.

## Key findings

- COPD patients showed decreased levels of nine metabolites compared to controls.
- Sex-specific differences in COPD include higher urate in men and altered creatine and bile-acid pathways.
- Metabolic patterns suggest systemic remodeling and sex-influenced heterogeneity in COPD.

## Abstract

Metabolomic studies in COPD reveal systemic metabolic perturbations, yet sex is often treated as a covariate rather than a biological driver. We aimed to identify plasma metabolites differentiating COPD from controls and to define sex-specific metabolic signatures in both groups. Methods: In this controlled observational study (BIOMEPOC cohort), untargeted plasma metabolomics was performed by LC-MS/MS. Differential abundance was tested across four contrasts (COPD vs. controls; men vs. women within controls; men vs. women within COPD; sex-by-disease interaction) with a false discovery rate (FDR) correction. Because smoking history differed between COPD and controls, a post hoc ever-smokers analysis was conducted. Results: COPD differed from controls in nine metabolites (all decreased): DL-stachydrine, 3-methyl-L-histidine, fructose, pipecolinic and nipecotic acids, 5-nitro-o-toluidine, conjugated linoleic acid, aminoadipate, and creatinine. This pattern is compatible with metabolic depletion, remodeling, and/or altered flux across multiple compartments rather than simple substrate deficiency, spanning muscle-related pools, amino acid handling, carbohydrate-associated metabolism, and exposome-linked inputs. In ever-smokers, results were directionally consistent, with five metabolites remaining nominally significant. Among controls, five metabolites were higher in men after FDR correction (PABA, cis-4-hydroxy-D-proline, N-acetylasparagine, deoxycarnitine, and creatinine), consistent with physiological sex dimorphism in energy pathways, connective-tissue remodeling, and diet/microbiome-related metabolism. Within COPD, six metabolites differed by sex after FDR correction, defining three axes: creatine energy buffering (men: higher GAA/creatinine, lower creatine), purine/urate handling (men: higher urate), and conjugated bile acids (men: higher GCDCA), implicating muscle bioenergetics, redox/inflammatory tone, and gut–liver crosstalk. Conclusions: Plasma metabolomics identifies a pattern compatible with systemic remodeling in COPD and sex-associated divergences in creatine, purine/urate, and bile-acid pathways, supporting a sex-influenced view of systemic COPD heterogeneity and highlighting targets for mechanistic validation.

## Linked entities

- **Chemicals:** DL-stachydrine (PubChem CID 555), 3-methyl-L-histidine (PubChem CID 64969), fructose (PubChem CID 5984), pipecolinic acid (PubChem CID 849), nipecotic acid (PubChem CID 4498), 5-nitro-o-toluidine (PubChem CID 7444), aminoadipate (PubChem CID 469), creatinine (PubChem CID 588), PABA (PubChem CID 978), cis-4-hydroxy-D-proline (PubChem CID 440014), N-acetylasparagine (PubChem CID 99715), deoxycarnitine (PubChem CID 725), GAA (PubChem CID 10465927), urate (PubChem CID 1175), GCDCA (PubChem CID 12544)
- **Diseases:** COPD (MONDO:0005002)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, GAMT (guanidinoacetate N-methyltransferase) [NCBI Gene 2593] {aka CCDS2, HEL-S-20, PIG2, TP53I2}, GATM (glycine amidinotransferase) [NCBI Gene 2628] {aka AGAT, AT, CCDS3, FRTS, FRTS1, RFS}, GAA (alpha glucosidase) [NCBI Gene 2548] {aka IOPD, LOPD, LYAG}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}, ENPP2 (ectonucleotide pyrophosphatase/phosphodiesterase 2) [NCBI Gene 5168] {aka ATX, ATX-X, AUTOTAXIN, LysoPLD, NPP2, PD-IALPHA}, GPBAR1 (G protein-coupled bile acid receptor 1) [NCBI Gene 151306] {aka BG37, GPCR19, GPR131, M-BAR, TGR5}
- **Diseases:** cholestasis (MESH:D002779), hypertension (MESH:D006973), inflammation (MESH:D007249), cardiovascular abnormalities (MESH:D018376), metabolic disorders (MESH:D008659), muscle dysfunction (MESH:D009135), arterial hypertension (MESH:D000081029), overweight (MESH:D050177), hypoxemia (MESH:D000860), loss of functional capacity (MESH:D006315), obstructive lung disease (MESH:D008173), Cardiovascular comorbidities (MESH:D002318), GOLD group E (MESH:D001260), mitochondrial dysfunction (MESH:D028361), diabetes (MESH:D003920), COPD (MESH:D029424), insulin resistance (MESH:D007333), injury to (MESH:D014947), sarcopenic obesity (MESH:D009765), type 2 diabetes mellitus (MESH:D003924), Renal dysfunction (MESH:D007674), lung cancer (MESH:D008175), metabolic malnutrition (MESH:D044342), sarcopenia (MESH:D055948)
- **Chemicals:** GCDCA (MESH:D005999), metformin (MESH:D008687), carbohydrate (MESH:D002241), acylcarnitine (MESH:C116917), amine (MESH:D000588), ATP (MESH:D000255), 5-nitro-o-toluidine (MESH:C065026), steroid (MESH:D013256), acetyl-CoA (MESH:D000105), N-acetylasparagine (MESH:C026988), PABA (MESH:D010129), thiazide (MESH:D049971), Deoxycarnitine (MESH:C002889), mannose (MESH:D008358), urea (MESH:D014508), glucose (MESH:D005947), 1-methyl-L-histidine (MESH:C028120), acetylphosphate (MESH:C011632), malate (MESH:C030298), glycine (MESH:D005998), glycerophospholipids (MESH:D020404), Creatinine (MESH:D003404), PCs (MESH:D010713), lysine (MESH:D008239), phosphate (MESH:D010710), PUFA (MESH:D005231), Urate (MESH:D014527), RNS (MESH:D026361), L-methionine sulfoxide (MESH:C013111), folate (MESH:D005492), isoleucine (MESH:D007532), Cer (MESH:D002518), 4-aminobenzoate (MESH:D062366), GSH (MESH:D005978), Pi (MESH:D010716), ARA (MESH:D016718), leucine (MESH:D007930), Bile acids (MESH:D001647), GAA (MESH:C043055), D-(-)-fructose (MESH:D005632), amino acid (MESH:D000596), valine (MESH:D014633), purines (MESH:D011687), stachydrine (MESH:C003342), acetylcarnitine (MESH:D000108), sphingolipids (MESH:D013107), endocannabinoid (MESH:D063388), guanidinoacetate (MESH:C004946), 3-methyl-L-histidine (MESH:C028118), lysophosphatidic acid (MESH:C032881), arginine (MESH:D001120), DHA (MESH:C027493), SMs (MESH:D013109), sarcosine (MESH:D012521), eicosanoid (MESH:D015777), hippurate (MESH:C030514), lysophospholipids (MESH:D008246), nipecotic acids (MESH:D009557), lipid (MESH:D008055), LA (MESH:D007811)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Prevotella (genus) [taxon 838], Bifidobacterium (genus) [taxon 1678], Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606], gut metagenome (species) [taxon 749906]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027610/full.md

---
Source: https://tomesphere.com/paper/PMC13027610